A recent review published in Genes & Diseases sheds light on the complex and multifaceted role of RNA-binding proteins (RBPs) in cancer progression, with a particular focus on the fragile X mental retardation protein (FMRP).

Traditionally recognised for its critical functions in neural development, FMRP is now emerging as a key regulator in cancer biology, influencing tumour growth, metastasis, and therapy resistance.

This growing body of knowledge presents a shift in understanding how RNA metabolism can drive oncogenic processes and potentially offer novel diagnostic and therapeutic strategies.

FMRP plays a dual role in cancer, acting both as a tumour suppressor and promoter, depending on the cellular context.

Its ability to regulate mRNA stability, translation, and transport positions it as a crucial factor in the intricate network of gene expression that governs cancer progression.

Studies indicate that low levels of FMRP are associated with decreased tumour development in some cases, whereas high expression is linked to aggressive cancers, including breast, colorectal, and hepatocellular carcinomas.

The variability in FMRP’s impact on different tumour types underscores the necessity for a nuanced approach when considering it as a therapeutic target.

One of the most significant findings discussed in the review is FMRP’s role in therapy resistance.

By interacting with key oncogenic pathways, FMRP contributes to cancer cells' ability to withstand chemotherapy, radiation, and immunotherapy.

In colorectal cancer, FMRP stabilises epidermal growth factor receptor (EGFR) mRNA, enhancing tumour proliferation.

Additionally, its involvement in epithelial-mesenchymal transition (EMT) suggests a critical function in tumour metastasis.

Furthermore, its association with immune evasion mechanisms highlights its potential influence on the tumour microenvironment and response to immune checkpoint inhibitors.

The potential of targeting FMRP in cancer treatment is an area of growing interest.

By interfering with its ability to regulate oncogenic mRNAs, researchers aim to develop precision medicine strategies that can either inhibit its tumour-promoting functions or harness its tumour-suppressive capabilities.

Exploring the post-translational modifications (PTMs) of FMRP and its interplay with other RNA-binding proteins could pave the way for highly specific therapeutic interventions that mitigate its oncogenic effects while preserving essential cellular functions.

This evolving understanding of FMRP’s role in cancer underscores the complexity of RNA metabolism in tumorigenesis.

As scientists continue to investigate the intricate balance between FMRP’s tumour-suppressive and oncogenic functions, its potential as both a biomarker and therapeutic target is becoming increasingly evident.

Source: Compuscript Ltd